CRAMS outsourcing in pharmaceutical and chemical research and manufacturing Part I.
CRAMS Outsourcing – Political and macro-economical implications
Outsourcing Contract research and manufacturing services (CRAMS) in the pharmaceutical, bio-technological and chemical industry is massive, a multi-billion dollar business. We will outline in this article how big is this business, what drives this business and what are the implications for enterprises and for the society ?
Political and macro-economical implications of outsourcing
But first let us look at outsourcing in general. Offshore “outsourcing is a problem for the US and the first world in general, because all tradable goods production and service jobs can be outsourced“, according to a McKinsey study[i], in the years 2003-2008 the number of jobs outsourced in service sectors would as by their forecast grow from 18 mio to 160 mio. It is a massive trend, affecting a segment of the workforce that was never in history subject to this kind of competition, thereof engineering most drastically affected with 55% „occupations amenable for remote locations“.
The global market for outsourcing services is seen almost 400 bio USD with a long-term growth of 6%, thereof 240 bio USD in IT services being by far the biggest sector[ii] (Gartner, 2012).
To read the full article, please login. The full content of this article and all premium articles is available exclusively for site members.
Site membership is free. If you are an existing user, please login. New users may register below.